Genfit Not Fully Exiting NASH, Despite Terminating RESOLVE-IT
Executive Summary
A fuller look at interim Phase III data shows no path forward to accelerated approval in NASH, company says. Genfit turns focus to developing elafibranor for PBC, as well as a NASH diagnostic.
You may also be interested in...
Deal Watch: Private Equity-Backed Covis Bids To Buy Troubled AMAG
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
Poxel’s Phase II Data Add AMP Kinase Activation To NASH Possibilities
Recent development upheaval in non-alcoholic steatohepatitis has created opportunity for new approaches, and Poxel thinks its AMPK activator may address several NASH-related pathologies.
Zydus Cadila Readies Injectables Push
Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and the firm has just launched its Remdac version of remdesivir.
Need a specific report? 1000+ reports available
Buy Reports